AstraZeneca announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol.
Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Media Enquiries
Neil Burrows UK/Global +44 7842 350541Vanessa Rhodes UK/Global +44 7880 400690
Karen Birmingham UK/Global +44 7818 524012
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Enquiries : UK
Thomas Kudsk Larsen +44 7818 524185Nick Stone RIA +44 7717 618834
Henry Wheeler +44 7788 354619
Craig Marks Finance +44 7881 615764
Christer Gruvris +44 7827 836825
US
Lindsey Trickett CVMD +1 240 543 7970Mitch Chan Oncology +1 240 477 3771
Dial / Toll-Free +1 866 381 7277
